Which agent represents emerging GLP-1 agonist therapy in OA?

Which agent represents emerging GLP-1 agonist therapy in OA?

• A. Retatrutide
• B. Liraglutide
• C. Dulaglutide
• D. Semaglutide

Answer: (A)

Emerging therapies in OA are exploring how metabolic benefits, especially weight loss and reduced systemic inflammation, can translate into better joint outcomes. Retatrutide fits this idea as a next-generation, multi-receptor agent that combines GLP-1 receptor activation with additional gut hormone targets. This broader action aims to produce greater weight loss and metabolic improvements than traditional GLP-1 drugs, which could meaningfully impact OA symptoms and progression. That’s why retatrutide is considered the emerging GLP-1–related approach in OA. The other drugs listed are established GLP-1 receptor agonists used for diabetes or obesity, with well-known effects on weight and glucose but without being framed as emerging OA therapies.

Emerging therapies in OA are exploring how metabolic benefits, especially weight loss and reduced systemic inflammation, can translate into better joint outcomes. Retatrutide fits this idea as a next-generation, multi-receptor agent that combines GLP-1 receptor activation with additional gut hormone targets. This broader action aims to produce greater weight loss and metabolic improvements than traditional GLP-1 drugs, which could meaningfully impact OA symptoms and progression. That’s why retatrutide is considered the emerging GLP-1–related approach in OA.

The other drugs listed are established GLP-1 receptor agonists used for diabetes or obesity, with well-known effects on weight and glucose but without being framed as emerging OA therapies.